loading
Century Therapeutics Inc stock is traded at $1.245, with a volume of 299.25K. It is up +1.64% in the last 24 hours and down -22.50% over the past month. Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
See More
Previous Close:
$1.22
Open:
$1.23
24h Volume:
299.25K
Relative Volume:
0.78
Market Cap:
$108.84M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.5737
EPS:
-2.17
Net Cash Flow:
$-102.08M
1W Performance:
-15.65%
1M Performance:
-22.50%
6M Performance:
-58.80%
1Y Performance:
-10.14%
1-Day Range:
Value
$1.21
$1.29
1-Week Range:
Value
$1.20
$1.50
52-Week Range:
Value
$1.14
$5.51

Century Therapeutics Inc Stock (IPSC) Company Profile

Name
Name
Century Therapeutics Inc
Name
Phone
215-981-4000
Name
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Name
Employee
165
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
IPSC's Discussions on Twitter

Compare IPSC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
IPSC 1.245 108.84M 2.24M -136.67M -102.08M -2.17
VRTX 467.19 119.83B 10.63B -479.80M -1.35B 13.33
REGN 760.91 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 566.22 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.39 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.55 24.08B 3.30B -501.07M 1.03B 11.54

Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-27-22 Initiated Chardan Capital Markets Buy
Oct-31-22 Initiated Guggenheim Buy
Oct-10-22 Initiated Canaccord Genuity Buy
May-23-22 Initiated H.C. Wainwright Buy
May-12-22 Initiated William Blair Mkt Perform
Jul-13-21 Initiated BofA Securities Buy
Jul-13-21 Initiated JP Morgan Overweight
Jul-13-21 Initiated Piper Sandler Overweight
View All

Century Therapeutics Inc Stock (IPSC) Latest News

pulisher
08:02 AM

Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace

08:02 AM
pulisher
Nov 14, 2024

Syncona Portfolio Ltd's Strategic Acquisition of Autolus Therape - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

FMR LLC's Strategic Reduction in Century Therapeutics Inc Holdin - GuruFocus.com

Nov 13, 2024
pulisher
Nov 11, 2024

NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve

Nov 11, 2024
pulisher
Nov 11, 2024

Carisma Therapeutics and Moderna Unveil Promising Pre-Clinical Data for Anti-GPC3 CAR-M Therapy - MyChesCo

Nov 11, 2024
pulisher
Nov 11, 2024

Century Therapeutics to Present Cutting-Edge Preclinical Data at 2024 ASH Annual Meeting - MSN

Nov 11, 2024
pulisher
Nov 10, 2024

Ocugen Advances Gene Therapy and Financial Strategies in Q3 2024 - MyChesCo

Nov 10, 2024
pulisher
Nov 09, 2024

William Blair Has Positive Estimate for IPSC FY2024 Earnings - Defense World

Nov 09, 2024
pulisher
Nov 09, 2024

Palvella Therapeutics Begins Phase 3 Trial for Microcystic Lymphatic Malformations Treatment - MyChesCo

Nov 09, 2024
pulisher
Nov 09, 2024

Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 09, 2024
pulisher
Nov 09, 2024

FY2024 Earnings Estimate for IPSC Issued By HC Wainwright - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

Context Therapeutics Announces Q3 2024 Financial Results and Strategic Advances - MyChesCo

Nov 08, 2024
pulisher
Nov 08, 2024

What Makes Century Therapeutics (IPSC) a New Buy Stock - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

What is HC Wainwright's Forecast for IPSC FY2024 Earnings? - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

William Blair Has Strong Estimate for IPSC FY2024 Earnings - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Century Therapeutics Expands Clinical Focus and Reports Steady Financials for Q3 2024 - MSN

Nov 08, 2024
pulisher
Nov 08, 2024

Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim's Healthcare Innovation Conference! - MyChesCo

Nov 08, 2024
pulisher
Nov 08, 2024

Aclaris Therapeutics Highlights Key Advances and Financial Results for Q3 2024 - MyChesCo

Nov 08, 2024
pulisher
Nov 08, 2024

Passage Bio CEO Will Chou to Share Insights at Guggenheim Healthcare Innovation Conference! - MyChesCo

Nov 08, 2024
pulisher
Nov 07, 2024

Chardan Capital Has Lowered Expectations for Century Therapeutics (NASDAQ:IPSC) Stock Price - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Century Therapeutics, Inc. Demonstrates Strong Financial Management with No Senior Securities Defaults - TipRanks

Nov 07, 2024
pulisher
Nov 06, 2024

Join Century Therapeutics at Guggenheim’s Healthcare Innovation Conference! - MyChesCo

Nov 06, 2024
pulisher
Nov 06, 2024

Century Therapeutics shares target cut, retains Buy rating on updated data - Investing.com UK

Nov 06, 2024
pulisher
Nov 06, 2024

HC Wainwright Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $5.00 - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Century Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

Century Therapeutics COO sells $1,267 in stock - Investing.com

Nov 06, 2024
pulisher
Nov 05, 2024

Century Therapeutics Reports Q3 Results & Strategic Updates - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Century Therapeutics COO sells $1,267 in stock By Investing.com - Investing.com UK

Nov 05, 2024
pulisher
Nov 05, 2024

Century Therapeutics earnings beat by $0.08, revenue topped estimates - Investing.com UK

Nov 05, 2024
pulisher
Nov 05, 2024

InventHelp Inventor Develops Protective Accessory for Underwear (ASP-336) - Yahoo Finance

Nov 05, 2024
pulisher
Nov 05, 2024

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of - The Bakersfield Californian

Nov 05, 2024
pulisher
Nov 05, 2024

Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting - Yahoo Finance

Nov 05, 2024
pulisher
Nov 04, 2024

Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025 - Yahoo Finance

Nov 04, 2024
pulisher
Nov 04, 2024

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - The Manila Times

Nov 04, 2024
pulisher
Nov 04, 2024

Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference - GlobeNewswire

Nov 04, 2024
pulisher
Oct 31, 2024

Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MyChesCo

Oct 31, 2024
pulisher
Oct 28, 2024

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate - Yahoo Finance

Oct 28, 2024
pulisher
Oct 25, 2024

Context Therapeutics to Engage Investors at November Conferences - MyChesCo

Oct 25, 2024
pulisher
Oct 22, 2024

electroCore (ECOR) Stock Jumps 11.7%: Will It Continue to Soar? - Yahoo Finance

Oct 22, 2024
pulisher
Oct 17, 2024

Context Therapeutics to Showcase Promising Cancer Therapy at SITC Annual Meeting - MyChesCo

Oct 17, 2024
pulisher
Oct 16, 2024

Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 6.4% in September - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

As the Cell Therapy Market Eyes $48 Billion, Bayer Invests $215 Million in Century Therapeutics As Revealed... - WhaTech

Oct 16, 2024
pulisher
Oct 15, 2024

Dimensional Fund Advisors LP Acquires New Shares in Zai Lab Limited (NASDAQ:ZLAB) - Defense World

Oct 15, 2024
pulisher
Oct 15, 2024

Artiva, Century, others extend natural-killer autoimmune push - BioWorld Online

Oct 15, 2024
pulisher
Oct 15, 2024

Ubiquiti Inc. (NYSE:UI) Shares Sold by Dimensional Fund Advisors LP - Defense World

Oct 15, 2024
pulisher
Oct 05, 2024

American Century Companies Inc. Has $128,000 Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World

Oct 05, 2024
pulisher
Oct 05, 2024

American Century Companies Inc. Acquires 36,528 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World

Oct 05, 2024
pulisher
Oct 05, 2024

American Century Companies Inc. Boosts Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Oct 05, 2024

Century Therapeutics Inc Stock (IPSC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Century Therapeutics Inc Stock (IPSC) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Carr Douglas
SVP Finance & Operations
Nov 04 '24
Sale
1.23
283
347
317,147
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.25
price down icon 0.96%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):